Novartis AG NVS
160.25 USD -0.07 (-0.04%)
At closeNov 12, 2026, 5:31 PM EST
160.25 0.00 0.00%
After hours · Nov 12, 5:31 PM ET
159.93 Day range 161.31
124.36 52-week range 168.62
- YTD
- +16.23%
- 1 year
- +21.14%
News
zacks.com Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
benzinga.com PepGen Stock Doubles in One Session - Here's Why PepGen reports positive Phase 2 results for PGN-EDODM1 in DM1, showing record splicing correction and notable functional improvements.
defenseworld.net Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS Commonwealth Equity Services LLC increased its holdings in Novartis AG (NYSE: NVS) by 2.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 152,688…
zacks.com 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026 In the Large-Cap Pharmaceuticals industry, LLY, NVS and BAYRY are worth watching as the industry shows a strong recovery.
benzinga.com $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today Novartis (NYSE:NVS) has outperformed the market over the past 5 years by 6.13% on an annualized basis producing an average annual return of 15.55%. Currently, Novartis has a market capitalization of…
fool.com Novartis: 3 Key Takeaways for Long-Term Investors Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.
zacks.com 3 Stocks to Watch Following Guidance Upgrades The Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
prnewswire.com BioArctic collaborator Novartis terminates agreement STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option,…
marketwatch.com 6 dividend stocks for investors who want to cut their exposure to the S&P 500 Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.
benzinga.com Allarity Therapeutics Settles $4.9M Novartis Liability For $1M Payment On October 28, 2026, Allarity Therapeutics, Inc. (the "Company") entered into a Settlement and Release Agreement (the "Settlement Agreement") with Novartis Pharma AG ("Novartis") relating to an
reuters.com Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
cnbc.com Companies promised AI gains— here's how the payoff showed up in earnings Companies including Santander, Novartis and Standard Chartered say artificial intelligence is beginning to contribute to revenue, costs or profitability. Santander said AI initiatives generated 194…
seekingalpha.com Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach Novartis is rated Hold, with a 12-month price target of $141.81, implying a 12.0% downside from the current share price. My model indicates near-term pressure on selected products, while projected…
zacks.com All You Need to Know About Novartis (NVS) Rating Upgrade to Buy Novartis (NVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com Why Novartis (NVS) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
cnbc.com A pharma giant is moving past one patent cliff — but another is already looming Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a…
seekingalpha.com Novartis AG (NVS) Q3 2026 Earnings Call Transcript Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief…
zacks.com These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
benzinga.com Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
benzinga.com Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
marketbeat.com What Novartis (NVS) Said on Its Q3 Earnings Call Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core…
zacks.com 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
zacks.com NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
benzinga.com Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges,…
benzinga.com Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit Novartis beat Q3 adjusted earnings estimates despite a $1.9 billion Avidity impairment charge, lifted by strong sales of Kisqali, Kesimpta, and revised guidance.
zacks.com Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Novartis Q3 2026 Earnings Call Transcript Novartis (NYSE:NVS) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 10 Futures Gain as Fed Begins Its Two-Day Meet— Novartis, HSBC, Welltower in Focus (UPDATED) U.S. stock futures were mixed on Tuesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices moved in different directions.- benzinga.com Novartis Keeps FY 2026 Net Sales Growth At Low Single-Digit, Raises Core Operating Income Outlook To In Line To Low Single-Digit Growth Full-year 2026 guidance raised for core operating income o Net sales expected to grow low single-digit (unchanged) o Core operating income expected to be in line to grow low single-digit (from…
benzinga.com Novartis Q3 Adj. EPS $2.46 Beats $2.27 Estimate, Sales $14.522B Miss $14.582B Estimate Novartis (NYSE:NVS) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.27 by 8.37 percent. This is a 9.33 percent increase over earnings of $2.25 per share…
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Futures edge higher as earnings, the Fed meeting and Anthropic IPO drive markets; oil falls as traders see 67% odds of an S&P 500 up open.
benzinga.com Visa, Coca-Cola On Deck Tuesday As Payments Growth, Global Demand Face Test Visa is Tuesday’s most material report, with investors looking for continued payments growth after a strong run in the stock. Coca-Cola, HSBC Holdings, Novartis, Boeing and S&P Global report before…
benzinga.com FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives FDA approves Novartis’s Rhapsido for symptomatic dermographism, marking the first treatment for adults with friction-triggered chronic hives- benzinga.com Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-cs…
benzinga.com Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
benzinga.com Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform Novartis halted its mid-stage ALS drug trial for VHB937 but exercised a $125 million option to acquire Sironax's brain delivery platform.
benzinga.com Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.- benzinga.com HSBC Upgrades Novartis to Hold, Raises Price Target to $136 HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price target from $123 to $136.
benzinga.com Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, and an upgraded sovereign AI partnership with Fujitsu.
benzinga.com A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
benzinga.com Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.
benzinga.com QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000 Amgen sank 9.8% Tuesday after Novartis' pelacarsen missed its Phase 3 endpoint, casting doubt on rival Lp(a) drug olpasiran.
benzinga.com S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today Crude near $98 pushes the 10-year Treasury yield above 4.8% for the first time since 2023, hammering the Dow as traders price a Fed rate hike next week.
benzinga.com What's Going On With Amgen Stock Tuesday? AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets- benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
benzinga.com Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED) Stock Market Today: S&P 500, Dow Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.